NewsRx

Search our medical news database

Aida Pharmaceuticals

Aida Pharmaceuticals completes phase I trials for gene-therapy drug

Published in Food and Drug Law Weekly, August 25th, 2006

Aida Pharmaceuticals, Inc., (AIDA), one of mainland China's leading pharmaceutical companies, announced that the company has successfully concluded the phase I trials for gene-therapy anti-tumor drug Rh-Apo2L.

Rh-Apo2L was approved for clinical trials in May 2005 by China's State Food and Drug Administration (SFDA). The trials were conducted from September 2005 through May 2006 at the Chinese Academy of Medical Sciences Oncology Hospital in Beijing, China.

The phase I clinical trials included 20 patients with advanced-stage malignant tumors. The researched cancer types included non-Hodgkin lymphoma, sarcoma, adrenal gland cortical tumors, non-small...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook